Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Nov 11, 2021 8:30 AM - Nov 12, 2021 1:00 PM

(Central Europe Standard Time)

Joint DIA/MEB “Excellence in Pharmacovigilance” Module 2: Safety Aspects in Clinical Trials

Module 2 will provide the safety reporting requirements, the roles, and responsibilities of all stakeholders in clinical trials.

Faculty

Wendy  Huisman, PharmD

Wendy Huisman, PharmD

Director, Vigifit, Netherlands

Over the past 25 years Wendy has been dedicated to pharmacovigilance. She has broad experience as EU QPPV for generic and innovative products in complex companies. She also has wealth of experience in lobbying and networking in trade associations/working groups. In her current role, Wendy provides pharmacovigilance support to Pharmaceutical Industry and SMEs (startups). She enjoys setting up the PV system and supports in the development of the PSMF with associated documents. Since 2020 Wendy is a trained professional in Transactional Analysis (TA). TA is a theory of human personality and social behavior. TA gives a wealth of options to work with challenges and changes in organisational and personal development.

Helen  Morrison, MA

Helen Morrison, MA

Global Periodic Reports Officer, Global Patient Safety & Pediatrics, Amgen, United Kingdom

Helen is currently the Periodic Reports Officer within Amgen. With over 20 years’ pharmaceutical industry experience across a number of organisations including various roles of increasing responsibility in Regulatory Affairs, Medical Information and Pharmacovigilance. Helen holds an M.A in Natural Sciences from the University of Cambridge.

Evelyn  Mulder-Olthof

Evelyn Mulder-Olthof

Pharmacovigilance Assessor, Medicines Evaluation Board (MEB), Netherlands

Evelyn Olthof studied biomedical sciences and has a PhD in medicines. She works as an assessor at the pharmacovigilance department of the Dutch national agency (MEB) for 5 years, and has high experiences in signal detection and Eudravigilance data analysis.

Elke  Stahl, PhD

Elke Stahl, PhD

Senior Expert, Clinical Trials Department, Federal Institute For Drugs and Medical Devices (BfArM), Germany

Dr. Elke Stahl, Clinical Trial Unit BfArM, Germany. Clinical Trials Senior Expert. CoChair of the Clinical Trial Facilitation Group (CTFG) till 2022. Involved in EMA’s EU CTIS groups as BfArM’s representative, National Contact Point for the CTR in Germany, representative in European Commissions CT working groups. Prior BfArM 10 years experiences as a pharmacokineticist at Bayer HealthCare AG, Germany, in early research up to candidate selection. PostDoc at Hoffmann-La Roche Inc and University of North Carolina (UNC). Ph.D. in pharmacology and licenced pharmacist.

Fakhredin Sayed Tabatabaei, MD, PhD

Fakhredin Sayed Tabatabaei, MD, PhD

Senior Assessor, MEB, Netherlands

Fakhredin Sayed Tabatabaei is a medical doctor and epidemiologist, working as Senior Assessor Pharmacovigilance at the Dutch national agency (MEB) for more than 17 years. He is also the chairman of the CMDh HaRP Project (Harmonization of Risk Management Plan). Fakhredin was an active member of the European Pioneer Group drafting the electronic product information (ePI) Key Principles that is published in 2020, and he is currently involved in the ePI Pilot Project in the Netherlands. Besides, he is the MEB representative in the Gravitate Health project, and the Network Subject Matter Expert in the Product Management Services (PMS) project.

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.